- Report
- January 2024
- 157 Pages
Global
From €5361EUR$5,550USD£4,584GBP
- Report
- February 2024
- 175 Pages
Global
From €4830EUR$5,000USD£4,130GBP
- Drug Pipelines
- April 2024
- 150 Pages
Global
From €2415EUR$2,500USD£2,065GBP
- Drug Pipelines
- March 2024
- 180 Pages
Global
From €2415EUR$2,500USD£2,065GBP
- Report
- July 2023
- 290 Pages
Global
From €3477EUR$3,600USD£2,974GBP
- Report
- July 2020
- 1200 Pages
Japan
From €2898EUR$3,000USD£2,478GBP
- Report
- June 2020
- 753 Pages
Global
From €3188EUR$3,300USD£2,726GBP
- Report
- April 2023
- 110 Pages
Global
From €4588EUR$4,750USD£3,923GBP
- Drug Pipelines
- March 2023
- 100 Pages
Global
From €2656EUR$2,750USD£2,271GBP
- Clinical Trials
- August 2022
- 150 Pages
Global
From €2415EUR$2,500USD£2,065GBP
- Report
- January 2019
- 50 Pages
Global
From €1449EUR$1,500USD£1,239GBP
- Report
- January 2022
- 224 Pages
Global
From €6713EUR$6,950USD£5,741GBP
- Drug Pipelines
- October 2020
- 79 Pages
Global
From €3381EUR$3,500USD£2,891GBP
- Drug Pipelines
- August 2018
- 119 Pages
Global
From €3381EUR$3,500USD£2,891GBP
- Report
- October 2022
- 94 Pages
Global
From €1932EUR$2,000USD£1,652GBP
- Report
- August 2022
- 78 Pages
Global
From €3381EUR$3,500USD£2,891GBP
- Drug Pipelines
- November 2018
- 134 Pages
Global
From €3381EUR$3,500USD£2,891GBP
Abemaciclib is a type of oncology drug used to treat certain types of cancer. It is a cyclin-dependent kinase (CDK) inhibitor, which works by blocking the activity of certain proteins that are involved in the growth and spread of cancer cells. Abemaciclib is used in combination with other cancer treatments, such as hormone therapy, chemotherapy, and targeted therapy. It is approved for the treatment of advanced or metastatic breast cancer, as well as for the treatment of non-small cell lung cancer.
Abemaciclib is a relatively new drug, having been approved by the US Food and Drug Administration (FDA) in 2017. It is the first CDK inhibitor to be approved for the treatment of advanced or metastatic breast cancer. Since its approval, it has become an important part of the oncology drug market.
Several companies are involved in the Abemaciclib market, including Eli Lilly and Company, Novartis, and Pfizer. These companies are involved in the research, development, and marketing of Abemaciclib. Show Less Read more